3 Result: Eisai
LEQEMBI Breakthrough: FDA Approves Eisai and Biogen's Alzheimer's Therapy
July 07th, 2023
Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) have received FDA approval for LEQEMBI (lecanemab-irmb), a groundbreaking treatment for Alzheimer's disease (AD), the most common type of dementia. LEQEMBI is the first approved therapy to demonstrate a . Read more
FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval
July 06th, 2023
Action Follows Confirmatory Trial to Verify Clinical Benefit Silver Spring, MD / CRWE PRESS RELEASE / July 06, 2023 - Today, the U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult p. Read more
Biogen: FDA Panel Backs OK of Alzheimer's Drug; Disc Medicine: Upgraded, Promising Trial Data
June 10th, 2023
Eisai and Biogen's (Nasdaq: BIIB) Alzheimer's drug candidate, LEQEMBI (lecanemab-irmb), received unanimous support from FDA PCNS panel based on Phase 3 Clarity AD trial data. The committee acknowledged its clinical benefit, overall benefit-r. Read more
Want To Find Some News?
News By Industries
Recent Post
-
FDA Approves Nerve Scaffold for the Treatment of Sensory Nerve Discontinuity
December 04th, 2025December 02nd, 2025Earnings Countdown: Salesforce, Snowflake, and Guidewire Take Center Stage
November 30th, 2025Wall Street Eyes CrowdStrike, Marvell Technology, and GitLab as Earnings Near
November 30th, 2025Earnings Preview: Credo Technology, MongoDB, and Hafnia in Focus
November 30th, 2025
Member Login